PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 3, 2026JCEM Case Reports0 citationsOpen Access

Primary adrenal insufficiency and autoimmune thyroiditis in an adolescent with Castleman-TAFRO syndrome

View Full Paper
MMManahil MustafaVAVasantha D. AaronKOKathleen Overholt

Key Points

  • To describe a rare case of primary adrenal insufficiency and autoimmune thyroiditis in an adolescent with Castleman-TAFRO syndrome.
  • Clinical examination and history taking
  • Lymph node biopsy for diagnosis
  • Glucocorticoid replacement therapy
  • Targeted immunosuppressive therapy with siltuximab
  • Patient exhibited severe inflammation, lymphadenopathy, and multiple organomegaly
  • Confirmed diagnosis of iMCD-TAFRO through biopsy
  • Successful management with glucocorticoids and anti-IL-6 monoclonal antibodies
  • Emergence of both primary adrenal insufficiency and autoimmune thyroiditis indicated broader autoimmune activity

Abstract

Abstract The idiopathic multicentric Castleman disease (CD)–TAFRO variant (iMCD-TAFRO) is a rare, clinically aggressive lymphoproliferative disorder characterized by thrombocytopenia, anasarca, fever, reticulin fibrosis/renal failure, and organomegaly. Associated with elevated inflammatory cytokines, iMCD-TAFRO can present severe systemic complications. Here, we report a previously healthy adolescent male presenting with severe systemic inflammation, diffuse lymphadenopathy, anasarca, renal impairment, and hepatosplenomegaly. His clinical course was complicated by suspected bilateral adrenal infarction leading to primary adrenal insufficiency (PAI) requiring glucocorticoid (GC) replacement and new-onset autoimmune thyroiditis (AIT) requiring thyroid hormone replacement, suggesting a broader autoimmune process. Diagnosis of iMCD-TAFRO was supported by a right iliac lymph node biopsy showing CD features. The patient was successfully treated with high-dose GC followed by targeted immunosuppressive therapy with siltuximab, an anti-interleukin-6 monoclonal antibody. This case highlights a rare presentation of iMCD-TAFRO syndrome in a pediatric patient with unique co-occurrence of 2 endocrinopathies; PAI and AIT. Prompt recognition of potential associated endocrinopathies and a multidisciplinary approach are critical for management and improved outcomes in this life-threatening condition.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Mustafa et al. (2026) studied this question.

synapsesocial.com/papers/69cf5e3d5a333a821460c679https://doi.org/10.1210/jcemcr/luag006
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Radiological Imaging Findings of Adrenal Abnormalities in TAFRO Syndrome: A Systematic Review2024 · 8 citations
  2. 2International, evidence-based consensus diagnostic criteria for HHV-8–negative/idiopathic multicentric Castleman disease2017 · 638 citations
  3. 3Peripheral hypothyroidism and TAFRO syndrome: Particularity of management2023 · 1 citations
  4. 4Thyroxine unmasks Addison's disease2004 · 35 citations
  5. 5Reversible Subclinical Hypothyroidism in the Presence of Adrenal Insufficiency2006 · 28 citations